Maia Wealth LLC Acquires 901 Shares of Eli Lilly and Company $LLY

Maia Wealth LLC lifted its position in shares of Eli Lilly and Company (NYSE:LLY) by 29.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,994 shares of the company’s stock after buying an additional 901 shares during the quarter. Maia Wealth LLC’s holdings in Eli Lilly and Company were worth $3,114,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the business. Silphium Asset Management Ltd lifted its position in Eli Lilly and Company by 8.4% during the second quarter. Silphium Asset Management Ltd now owns 4,777 shares of the company’s stock valued at $3,724,000 after acquiring an additional 370 shares during the last quarter. Correct Capital Wealth Management increased its holdings in shares of Eli Lilly and Company by 210.6% during the second quarter. Correct Capital Wealth Management now owns 1,488 shares of the company’s stock valued at $1,160,000 after acquiring an additional 1,009 shares in the last quarter. Country Trust Bank raised its position in shares of Eli Lilly and Company by 0.9% in the 2nd quarter. Country Trust Bank now owns 95,690 shares of the company’s stock valued at $74,593,000 after purchasing an additional 894 shares during the last quarter. Richmond Investment Services LLC boosted its stake in Eli Lilly and Company by 123.0% in the 2nd quarter. Richmond Investment Services LLC now owns 1,224 shares of the company’s stock worth $954,000 after purchasing an additional 675 shares in the last quarter. Finally, J.W. Cole Advisors Inc. grew its position in Eli Lilly and Company by 33.5% during the 2nd quarter. J.W. Cole Advisors Inc. now owns 25,109 shares of the company’s stock worth $19,573,000 after purchasing an additional 6,301 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock opened at $1,109.09 on Wednesday. The firm’s fifty day simple moving average is $869.19 and its 200-day simple moving average is $792.66. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,111.11. The stock has a market capitalization of $1.05 trillion, a price-to-earnings ratio of 72.49, a PEG ratio of 1.21 and a beta of 0.43. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, October 30th. The company reported $7.02 EPS for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm had revenue of $17.60 billion during the quarter, compared to the consensus estimate of $16.09 billion. During the same quarter last year, the firm earned $1.18 earnings per share. The firm’s revenue was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, equities analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th will be paid a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a dividend yield of 0.5%. The ex-dividend date of this dividend is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 29.35%.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the stock. JPMorgan Chase & Co. raised their price target on shares of Eli Lilly and Company from $1,050.00 to $1,150.00 and gave the stock an “overweight” rating in a report on Tuesday, November 18th. Cantor Fitzgerald increased their price target on shares of Eli Lilly and Company from $925.00 to $985.00 and gave the stock an “overweight” rating in a report on Friday, October 31st. Wall Street Zen raised Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 1st. Hsbc Global Res upgraded Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research report on Wednesday, August 27th. Finally, Guggenheim restated a “buy” rating and set a $948.00 target price on shares of Eli Lilly and Company in a report on Thursday, October 16th. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and seven have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,047.50.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.